Table 3.
Overview of mechanisms and animal studies of circRNAs in pancreatic cancer
| No | Circ | Position | Location | Mechanisms | Vivo functions | Pheno | Reference | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| miRNAs | Targets | RBPs | Pathways | Grow | Meta | ||||||
| 1 | ciRS-7 | chrX:q27.1 | miR-7 | EGFR | STAT3 | Onco | 30,898,507 | ||||
| 2 | 0000284 | chr11:33,307,958–33,309,057 | miR-124 | IL-6 | JAK-STAT3 | + | Onco | 29,255,366 | |||
| 3 | 0005273 | chr8:141,710,989–141,716,304 | KLF12 | Onco | 33,275,224 | ||||||
| 4 | chr12:74,678,804–74,700,449 | chr12:74,678,804–74,700,449 | Cyto | none | Onco | 32,879,441 | |||||
| 5 | 0001649 | chr6:146,209,155–146,216,113 | Suppr | 29,969,694 | |||||||
| 6 | ASH2L | Cyto (mainly) and nucl | miR-34a | Notch1 | EMT; VEGF | + | + | Onco | 31,718,694 | ||
| 7 | 0001460 | chr4:178,274,461–178,281,831 | Cyto | miR-432-5p | ADAR1 | GLI1 (A to I RNA-editing)-EMT/CCND; negative regulation of circNEIL3 | + | + | Onco | 33,750,389 | |
| 8 | 0013912 | chr1:145,601,529–145,601,852 | Cyto | miR-7-5p | EMT | + | Onco | 32,884,344 | |||
| 9 | 0050102 | chr19:18,459,757–18,466,821 | Cyto | miR-1182 | NPSR1 | + | onco | 33,289,016 | |||
| 10 | 0000662 | chr16:398,402–398,484 | Cyto | miR-361-3p | BTG2 | + | Suppr | 33,425,718 | |||
| 11 | 0000677 | chr16:16,101,672–16,162,159 | Onco | 33,413,045 | |||||||
| 12 | 0007534 | chr17:61,869,771–61,877,977 | miR‐625/892b | Bcl2/Bax; MMP2 | + | Onco | 30,382,592 | ||||
| 13 | 0001946 | chrX:q27.1 | miR-432-5p | E2F3 | + | Onco | 33,593,338 | ||||
| 14 | 0006215 | chr3:27,478,878–27,490,288 | miR-378-3p | SERPINA4 | Onco | 29,930,719 | |||||
| 15 | 0060055 | chr20:33,866,724–33,872,064 | miR-557 | SLC7A11 | PI3K/AKT | + | Onco | 33,469,368 | |||
| 16 | 0066147 | chr3:52,960,046–52,962,357 | Cyto | miR-330-5p | PAK1 | EMT | + | + | Onco | 32,855,541 | |
| 17 | 0071036 | chr4:143,324,090–143,326,477 | cyto (mainly) and nucl | miR-489 | + | Onco | 33,507,122 | ||||
| 18 | 0099999 | chr13:20,633,586–20,638,685 | miR-335-5p | JMJD2C | + | Onco | 30,537,731 | ||||
| 19 | IARS | miR-122 | RhOA | ZO1; F-actin | + | + | Onco | 30,064,461 | |||
| 20 | 0036627 | chr15:85,656,607–85,669,605 | Cyto (mainly) and nucl | miR-338 | MACC1 | MET | + | + | Onco | 29,709,702 | |
| 21 | ADAM9 | miR-217 | PRSS3 | ERK/VEGF | + | Onco | 31,810,373 | ||||
| 22 | 0000069 | chr1:47,745,912–47,748,131 | Cyto | miR-144 | STIL | + | Onco | 33,324,055 | |||
| 23 | 0009065 | chr16:14,738,130–14,738,466 | Cyto | miR-34b-5p | MET | AKT | + | + | Onco | 32,375,768 | |
| 24 | 0043278 | chr17:35,797,838–35,800,763 | Cyto | miR-455-3p | CD80 | cytokines | + | Onco | 33,505,218 | ||
| 25 | 0075829 | chr6:22,020,567–22,056,919 | Cyto | miR-1287-5p | LAMTOR3 | ERK/AKT | + | + | Onco | 33,184,989 | |
| 26 | chr7:154,954,255–154,998,784 | chr7:154,954,255–154,998,784 | miR-4459 | KIAA0513 | + | Onco | 33,042,405 | ||||
| 27 | LDLRAD3 | miR-137-3p | PTN | + | Onco | 31,521,692 | |||||
| 28 | 0001013 | chr2:61,339,656–61,345,251 | Cyto | miR-145 | KLF5 | MMP; VEGF | + | Onco | 33,563,550 | ||
| 29 | 0001568 | chr6:349,113–349,256 | Cyto (mainly) and nucl | miR-377 | HOXC6 | PCNA; VEGF; MMP; caspase3 | + | Onco | 32,193,152 | ||
| 30 | 0000979 | chr2:19,042,277–19,042,456 | Cyto | miR-223 | SLC4A4 | EMT; MMP; VEGF | + | Suppr | 32,878,470 | ||
| 31 | 0086375 | chr9:14,146,687–14,155,892 | Cyto | miR-486-5p | PIK3R1 | PI3K/VEGF | + | + | Suppr | 32,366,257 | |
| 32 | 03955 | miR-3662 | HIF-1a | + | Onco | 33,864,618 | |||||
| 33 | 0007334 | chr2:9,083,315–9,098,771 | Cyto | miR-433-3p | GOT1 | + | Onco | 33,832,516 | |||
| 34 | 0000977 | chr2:10,784,445–10,808,849 | miR-153 | HIF-1a; ADAM10 | Onco | 31,402,756 | |||||
| 35 | 0007367 | chr9:33,948,371–33,956,144 | miR-494 | CXCR4/ZEB1 | Onco | 31,584,877 | |||||
| 36 | 0002130 | chr19:6,702,137–6,702,590 | miR-4482-3p | NBN | Onco | 32,727,565 | |||||
| 37 | 0092314 | chr22:20,113,099–20,113,439 | Cyto | miR-761 | S100P | AKT/EMT | + | Onco | 33,842,379 | ||
| 38 | 0005397 | chr17:30,500,849–30,503,232 | Cyto | miR-26b-3p/125a-3p/330-5p/382-5p | MAPK; Wnt; Ras | Onco | 30,444,423 | ||||
| 39 | 0007334 | chr2:9,083,315–9,098,771 | miR-144-3p/miR-577 | MMP7; COL1A1 | Onco | 31,428,151 | |||||
| 40 | 0030235 | chr13:49,075,877–49,077,050 | miR-1253/miR-1294 | Onco | 30,591,218 | ||||||
| 41 | 0000816 | chr17:80,521,229–80,526,077 | Cyto | miR-942 | ANK1; GDNF; PAX6 | YBX1; hnRNPK | NUF2; PDXK | + | + | Onco | 32,217,695 |
| 42 | 0006988 | chr11:36,248,634–36,248,980 | Onco | 29,307,994 | |||||||
| 43 | chr14:101,402,109–101,464,448 | chr14:101,402,109–101,464,448 | miR-145-5p | Onco | 29,922,161 | ||||||
| 44 | chr4:52,729,603–52,780,244 | chr4:52,729,603–52,780,244 | miR-145-5p | Onco | 29,922,161 | ||||||
| 45 | 0000284 | chr11:33,307,958–33,309,057 | miR-330-5p | RASSF1 | EMT | + | Onco | 32,104,074 | |||
| 46 | 101672/004077/003251 | Onco | 29,781,033 | ||||||||
| 47 | 101543/002747/000926 | Suppr | 29,781,033 | ||||||||
cyto: cytoplasm; nucl: nucleus; miRNAs: microRNAs; RBPs: RNA binding proteins; Meta: Metastasis; Pheno: Phenomenon; onco: oncogene; suppr: suppressor